Affidea Expands in Italy, Lombardy region, Through Acquisition of Centro Radiologico Lodigiano

Affidea Expands in Italy, Lombardy region, Through Acquisition of Centro Radiologico Lodigiano
share Share

Affidea, the leading European provider of diagnostic imaging, outpatient and cancer care services has today announced the 100% acquisition of Centro Diagnostico Lodigiano (CRL), a well-known diagnostic imaging medical provider in Lodi, Lombardy region, Italy, a dense populated area of 230.000 inhabitants.


Since 2004, CRL medical center is the leading diagnostic imaging center in the area of the town of Lodi, a constantly growing commercial region in northern Italy. It offers advanced diagnostic imaging services in the range of MRI, CT, X-ray, US. Due to its reputed medical expertise and high-quality services with a patient centric approach, CRL has become a trusted partner of NHS in Lodi and its addition will further create synergies with the existing medical centers of Affidea in the region.


The deal was concluded as a result of a private negotiation where Affidea’s international reputation as trusted partner and high quality medical provider was the key catalyst for securing the transaction. This investment strengthens Affidea’s presence in Lombardy region – with the local network growing now to 55 centers. CRL acquisition comes as a further sign of Affidea’s commitment to Italy as a key market after the recently announced strategic acquisition of the Centro Diagnostic Cernaia | CDC Group, a renowned medical provider leading the occupational health, laboratory and private healthcare business in Piedmont region, Northern Italy that sets Affidea as the largest provider of outpatient and diagnostic imaging services, doubling its size across the country.

 

In Italy, the combined business of Affidea, CRL and CDC brings together almost 2500 professionals. With an extended network of 55 medical centers and 60 Blood Collection Points, the company will serve more than 2.2 million patients per year, expanding its range of medical services that will allow Affidea to be one of the preferred healthcare providers for corporations, private health insurers and NHS.


Giuseppe Recchi, Affidea CEO, said on the Affidea’s latest investment in Italy: “The acquisition of CRL and CDC underscores Affidea’s commitment to identify attractive healthcare businesses in Italy, a key market on our growth journey. Only this year we have successfully finalised six acquisitions in 5 countries in Europe  consolidating our European footprint leadership with 309 centers.  We have a long track record in building strong leading businesses in the countries where we are present, with a business model capable of creating synergies and providing best in class medical services. We will continue to pursue our ambitions to further invest in the healthcare industry, expand geographically and create sustainable value for our patients, doctors, payors, and our employees.” 

 

Dr. Regali, CRL's Medical Director, declares his enthusiasm and that of the whole team in joining the prestigious Affidea family: “Affidea is the ideal partner for taking CRL to the next stage of our development, benefitting from their unique international expertise, high quality standards and the integrated network of centers. With the support of Affidea I am sure we will be able to further develop new quality-oriented services for the benefit of our patients”.


Commenting on the acquisition, Fabio Silo, Country Manager of Affidea Italy, added: "The recent acquisition we made, CDC Group and CRL, position Affidea as a leading healthcare provider on the Italian market and a preffered provider for payors, be they public or private. Our enhanced capability and enlarged footprint allow us to offer a wider access to our services for patients, while at the same time cosolidating our position in the Italian healthcare market. CRL acquisition comes to prove that our core competences in diagnostic imaging remain a key focus in our business model, creating synergies with our outpatient capabilities. We look forward to continuing creating value for our patients in the new combined team.

 

CRL is the sixth acquisition that Affidea completes in the last seven months and demonstrates the continued commitment of the company to expand its presence in the markets where it is present and to strengthen its core competences in diagnostic imaging while expanding its business model into outpatient services. In December 2020, Affidea announced the acquisition of Sveti Rok, a reputed outpatient healthcare provider in Zagreb, Croatia. In January 2021, the company has announced the acquisition of Clinica Gamma in Spain. In March Affidea completed the acquisition of Orthoderm in Northern Ireland and Fortius clinic, the renowned provider specialised in orthopaedics and sports medicine in UK and in June Affidea announced the largest acquisition so far of CDC Group in Italy.



«« Siemens Healthineers Shape 21 HIMSS Experience


Is Your Hospital Ready for ANOTHER Wave of COVID-19? »»

Published on : Tue, 27 Jul 2021



Related Articles

Affidea , the leading diagnostic imaging, outpatient and cancer care provider, and GE Healthcare announce the launch of... Read more

Affidea, Affidea expansion, affidea italy Affidea Expands in Italy, Lombardy region, Through Acquisition of Centro Radiologico Lodigianoaff

No comment


Please login to leave a comment...